| Bourdin, Arnaud |
SECURE, NCT05626777: Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices |
|
|
| Active, not recruiting | 4 | 20 | Europe | Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month | Hospices Civils de Lyon, GlaxoSmithKline | Asthma | 03/26 | 07/26 | | |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
| Completed | 3 | 806 | Europe, Canada, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD DEVELOPMENT, LP | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
OCEAN, NCT05263934 / 2021-005726-15: Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
|
|
| Recruiting | 3 | 160 | Europe, Canada, Japan, US, RoW | Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab | GlaxoSmithKline | Eosinophilic Granulomatosis With Polyangiitis | 10/25 | 11/25 | | |
| Terminated | 3 | 186 | Europe, Canada, US, RoW | AV-101 | Aerovate Therapeutics, Aerovate Therapeutics Inc | Pulmonary Arterial Hypertension | 08/24 | 08/24 | | |
| Terminated | 2/3 | 202 | Europe, Canada, US, RoW | AV-101, Placebo | Aerovate Therapeutics, Aerovate Therapeutics, Inc. | Pulmonary Arterial Hypertension | 08/24 | 08/24 | | |
NCT04517916: Zephyr Etude Post-Inscription (French Registry) |
|
|
| Active, not recruiting | N/A | 155 | Europe | Zephyr Valve, Zephyr System, BLVR | Pulmonx Corporation | Emphysema or COPD | 06/22 | 09/25 | | |
NCT05728749: A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes |
|
|
| Recruiting | N/A | 300 | Europe | Non-interventional | Chiesi SAS, Gesellschaft für Therapieforschung mbH | ASTHMA | 03/24 | 03/25 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Didier, Alain |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
NCT04438408: National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype. |
|
|
| Recruiting | N/A | 400 | Europe | questionaires | University Hospital, Toulouse, AstraZeneca | Asthma Chronic, Severe Asthma | 09/21 | 12/21 | | |
| Guilleminault, Laurent |
SECURE, NCT05626777: Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices |
|
|
| Active, not recruiting | 4 | 20 | Europe | Pre-filled syringe, mepolizumab 100 mg/month, Auto-injector pen, mepolizumab 100 mg/month | Hospices Civils de Lyon, GlaxoSmithKline | Asthma | 03/26 | 07/26 | | |
| Recruiting | 4 | 220 | Europe | Benralizumab Prefilled Syringe, Transcriptomic | Nantes University Hospital, AstraZeneca, Ministère de la Santé - France | Asthma; Eosinophilic, Severe Asthma | 10/26 | 11/26 | | |
| Completed | 3 | 445 | Europe, RoW | 5-grass mix SLIT-drops, SLIToneULTRA, Placebo | ALK-Abelló A/S, Syneos Health | Allergy | 09/23 | 09/23 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
NCT04438408: National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype. |
|
|
| Recruiting | N/A | 400 | Europe | questionaires | University Hospital, Toulouse, AstraZeneca | Asthma Chronic, Severe Asthma | 09/21 | 12/21 | | |
| Active, not recruiting | N/A | 576 | Europe | questionnaires | University Hospital, Toulouse, MSD France | Refractory Chronic Cough | 06/25 | 06/26 | | |
| Guibert, Nicolas |
NCT04517916: Zephyr Etude Post-Inscription (French Registry) |
|
|
| Active, not recruiting | N/A | 155 | Europe | Zephyr Valve, Zephyr System, BLVR | Pulmonx Corporation | Emphysema or COPD | 06/22 | 09/25 | | |
| Completed | N/A | 102 | Europe, RoW | AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System | Pulmonx Corporation | Emphysema, COPD, Severe Emphysema | 10/23 | 10/24 | | |
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema |
|
|
| Recruiting | N/A | 200 | Europe, US, RoW | AeriSeal System | Pulmonx Corporation | Emphysema, Pulmonary, Emphysema or COPD | 06/27 | 03/28 | | |
| Active, not recruiting | N/A | 464 | Europe, US | Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care | Nuvaira, Inc. | COPD | 10/24 | 09/28 | | |
| Not yet recruiting | N/A | 150 | NA | Treatment plus Optimal Medical Therapy, InterVapor, BTVA, Optimal Medical Therapy | Uptake Medical Technology, Inc., MedPass International | Emphysema | 07/25 | 07/26 | | |
| Marchandise, Sandrine Pontier |
| No trials found |
| Brouquieres, Danielle |
| No trials found |
